Cantor Fitzgerald analyst Yanni Souroutzidis reiterated an Overweight rating on Karyopharm Therapeutics (NASDAQ: KPTI).The analyst commented, "Our positive view of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE